

First-Half 2025 Results

18 September 2025



Disclaimer

- This presentation, including the oral presentation (together, the “Materials”) has been prepared by the management of Biotallys NV (the “Company”). The Materials must be treated confidentially and may not be distributed, passed on or otherwise disclosed. The Materials serve information purposes only and do not constitute a prospectus or any offer for sale or subscription of, or solicitation or invitation to buy or subscribe for, any securities of the Company. The Company’s business, operations, financial situation and prospects are subject to risks and uncertainties. A description of the most important risks and uncertainties can be found in the Company’s annual report available on its website (www.Biotallys.com)
- This presentation includes market share and industry data, which were obtained by the Company from industry publications, press releases, data published by government agencies, industry reports prepared by consultants and other market data providers and internal surveys. The third party sources the Company has used generally state that the information they contain has been obtained from sources believed to be reliable. Some of these third party sources also state, however, that the accuracy and completeness of such information is not guaranteed and that the projections they contain are based on significant assumptions. As the Company does not have access to the facts and assumptions underlying such market data, or statistical information and economic indicators contained in these third party sources, the Company is unable to verify such information and, while the Company believes it to be reliable, it cannot guarantee its accuracy or completeness.
- In addition, certain information in this document is not based on published data obtained from independent third parties or extrapolations therefrom, but rather is based upon the Company's best estimates, which are in turn based upon information obtained from trade and business organizations and associations, consultants and other contacts within the industries in which the Company operates, information published by its competitors and its own experience and knowledge of conditions and trends in the markets in which it operates. The Company cannot provide any assurance that any of the assumptions that it has made while compiling this data from third party sources are accurate or correctly reflect its position in the industry and none of its internal estimates have been verified by any independent sources. The Company makes no representation or warranty as to the accuracy or completeness of this information. The Company has not independently verified this information and, while the Company believes it to be reliable, it cannot guarantee its accuracy.
- You are responsible for protecting yourself against viruses and other destructive items. You are accessing the Materials is at your own risk and it is your responsibility to take precautions to ensure that they are free from viruses or other items of a destructive nature.
- The Materials are provided in conjunction with the oral presentation held by the Company and should not be taken out of context.
- The information contained in the Materials is subject to change without prior notice. The presentation of the Materials (or any part hereof) shall not create any implication that there has been no change in the information contained in the Materials since the date hereof or that there has been no change in the business or financial position of the Company or its subsidiary since the date hereof. The Company does not undertake to provide any additional information, update or keep current information contained in the Materials, or to remedy any omissions in or from the Materials and any opinions expressed in the Materials are subject to change without prior notice. The foregoing is in any event without prejudice to the Company's obligations under applicable law in relation to disclosure.
- The Materials contain certain forward-looking statements, sometimes identified by the words “believes,” “expects,” “predicts,” “intends,” “projects,” “plans,” “estimates,” “aims,” “foresees,” “anticipates,” “targets,” and similar expressions, which speak only as at the date of the Materials. Such statements reflect current views with respect to future events and are subject to risks and uncertainties. Forward-looking statements are based on current plans, estimates, projections and expectations. These statements are based on certain assumptions that may prove to be erroneous. No representations or warranties, express or implied, are given as to the achievement or reasonableness of, and no reliance should be placed on, such forward-looking statements, including any projections, estimates forecasts or targets contained herein.
- Nothing in this presentation constitutes an offer of securities for sale in the EEA, the United Kingdom, Switzerland, Japan, the United States or elsewhere. The securities of the Company are not registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”) and may not be offered, sold or otherwise transferred within the United States (as such term is defined in Regulation S under the Securities Act) unless registered under the Securities Act or pursuant to an exemption from such registration. There is no intention to register securities of the Company under the Securities Act.
- You acknowledge that all industrial and intellectual property rights to this presentation are and shall remain vested in the Company. By attending this presentation or accessing the Materials you shall not acquire any right, title, license to use, or interest in the presentation or the Materials.
- All of the trademarks, service marks and logos displayed in the Materials, including but not limited to Biotallys, AGROBODY, EVOCA are registered and unregistered trademarks of the Company or one of its affiliates. Except as expressly provided in the Materials, you may not reproduce, display or otherwise use trademarks without first obtaining the Company’s written permission.
- Biotallys and each of their logos are commercial names, trademarks or registered trademarks owned by Biotallys NV.

Kevin Helash, CEO



Key investment highlights

1

Growing market in need of innovation

World is outgrowing traditional crop protection and demanding safe, sustainable and novel solutions. Biologically-based solutions are the fastest growing category in a \$40bn market of fungicides & insecticides ¹

2

Leadership position in new Precision Biocontrols category

On track to cross key regulatory milestones in U.S. and E.U. in pioneering a new class of crop protection built on precision molecular design using specifically selected proteins to target pests and pathogens

3

Robust pipeline driven by scalable platform

Growing pipeline of bio-fungicides and bio-insecticides. Technology allows for expansion and scalability across crops, geographies and market categories

4

Highly competitive development costs and timelines

Estimated 8-to-10-years to develop a new product at a cost of \$20m-\$30m, a roughly 10X reduction vs. the c. \$350m cost to develop a new synthetic chemistry crop protection molecule ²

5

Partner-driven commercial strategy being executed

Strong licensing and co-development potential with leading global ag players looking to expand their bio-based offer to growers (pre-harvest) and the supply chain (post-harvest)

6



Attractive financial profile

Expect to achieve competitive margins in high-value crops – the fastest growing segment of crop protection market – while maintaining financial discipline









Biotals continues to advance toward commercialization

EVOCA™ is paving the way for Biotals' pipeline...

✓ Regulatory


-  EPA expected to finalize registration in Q4 2025
-  Dutch authorities' positive recommendation to the EU

✓ Intellectual property

-  21 published patent families in key regions:     
-  3 trademarks: **Biotals™** **AGROBODY™** **EVOCA™**
-  Extensive proprietary know-how

✓ Partnerships

-  Development
-  Manufacturing
-  Distribution



... While securing a breakthrough market position

- ✓ Limited competition on similar approaches
- ✓ No competitor as advanced in R&D, regulatory or distribution
- ✓ Proven regulatory and commercial traction
- ✓ Robust IP patents portfolio in key agricultural markets

Biotals is expected to set the new standard and build early market share


Leadership position in new Precision Biocontrols category

Biotals is pioneering Precision Biocontrols, a new category in the \$40bn fungicide & insecticide market: reliability and scale of chemical solutions with safety and environmental profile of biologicals







Clear partnering strategy empowering pipeline development

Deal structure customized to partner capabilities, resources and interests



Partnering guarantees scalable, economically-sustainable pipeline growth


-  **Accelerate market entry** through the high market shares from the top sector players
-  Leverage the **established go-to-market** channels from the industry leaders
-  **Limit capital outlays** to advance the pipeline and commercialize the products
-  Share margins strategically to **guarantee incentivization and alignment**



*Maximize
efficiency,
profitability
and market reach*

BioFun-6 second-generation fungicide demonstrating excellent performance with lower dose rates

Field trial results



Field trial description

- Trials commissioned by Biotallys and conducted by CRO's in Europe and the U.S.
- The BioFun-6 AGROBODY candidate:
 - ✓ performs as well as a chemical and as EVOCA at significantly lower dosage rates against botrytis in grapes
 - ✓ maintained the same disease suppression as EVOCA against powdery mildew in cucumbers when applied at half the dose rate, and outperformed a standard biological fungicide (similar results in tomatoes)


Luc Van fraeyenhoven, CFO



HY 2025 key financial highlights

In € thousands	June 30, 2025	June 30, 2024
Other operating income	1,379	1,452
Research and development expenses	(6,520)	(5,135)
General and administrative expenses	(2,988)	(2,890)
Operating loss	(8,129)	(6,574)
Loss of the period	(8,135)	(6,489)
Net cash used in operations	(6,092)	(6,527)
Net cash outflow of the period	(6,927)	(6,890)
Cash and cash equivalents	15,711	14,680

Biotalys is committed to disciplined capital deployment



1. Excluding equity raised; 2. Source: Dunham Trimmer; company estimates

Key investment highlights

1

Growing market in need of innovation

World is outgrowing traditional crop protection and demanding safe, sustainable and novel solutions. Biologically-based solutions are the fastest growing category in a \$40bn market of fungicides & insecticides ¹

2

Leadership position in new Precision Biocontrols category

On track to cross key regulatory milestones in U.S. and E.U. in pioneering a new class of crop protection built on precision molecular design using specifically selected proteins to target pests and pathogens

3

Robust pipeline driven by scalable platform

Growing pipeline of bio-fungicides and bio-insecticides. Technology allows for expansion and scalability across crops, geographies and market categories

4

Highly competitive development costs and timelines

Estimated 8-to-10-years to develop a new product at a cost of \$20m-\$30m, a roughly 10X reduction vs. the c. \$350m cost to develop a new synthetic chemistry crop protection molecule ²

5

Partner-driven commercial strategy being executed

Strong licensing and co-development potential with leading global ag players looking to expand their bio-based offer to growers (pre-harvest) and the supply chain (post-harvest)

6

Attractive financial profile

Expect to achieve competitive margins in high-value crops - the fastest growing segment of crop protection market - while maintaining financial discipline

Q&A



Kevin Helash
Chief Executive Officer



Luc Van fraeyenhoven
Chief Financial Officer

